Results for tag: "Cerebral Adrenoleukodystrophy Drug"

Cerebral Adrenoleukodystrophy (CALD) is a rare, inherited disorder of the central nervous system that affects the brain and spinal cord. It is caused by a mutation in the ABCD1 gene, which is responsible for the production of a protein that helps break down very long-chain fatty acids. Symptoms of CALD include progressive neurological deterioration, seizures, and vision and hearing loss. Treatment for CALD is limited to supportive care and dietary management. The Cerebral Adrenoleukodystrophy Drug market is a small but growing segment of the Central Nervous System Drugs market. Currently, there are no approved drugs for the treatment of CALD, but there are several drugs in clinical development. These drugs are designed to target the underlying cause of the disorder, and they are being developed by a number of pharmaceutical companies. Some of the companies in the Cerebral Adrenoleukodystrophy Drug market include Sanofi, Novartis, Pfizer, and Biogen. These companies are researching and developing drugs to treat CALD, and they are working to bring these drugs to market. Show Less Read more